Literature DB >> 23286947

Defining the impact of individual sample variability on routine immunoassay of serum free light chains (sFLC) in multiple myeloma.

S H K Murng1, L Follows, P Whitfield, J A Snowden, K Swallow, K Green, R Sargur, W Egner.   

Abstract

Serum free light chain (sFLC) measurement has gained widespread acceptance and is incorporated into various diagnostic and response criteria. Non-linearity and antigen excess are the main causes of 'variability' in the measurement of sFLC using immunoassay, but the impact of these on measurement has been unclear. We performed a retrospective evaluation using a dilutional strategy to detect these phenomena. A total of 464 samples in 2009 and 373 samples in 2010 were analysed for sFLC. Non-linearity was detected in both high and apparently normal sFLC. Major non-linearity of more than twofold is common in high kappa (20·2%) and lambda (14·1%). It is less common in samples with apparently normal levels - kappa (6·4%) and lambda (9·5%). 9·4% of kappa and 15·5% of lambda showed antigen excess at screening dilutions. 34·4% of the samples had either non-linearity or antigen excess. We conclude that significant measurement variability is common in the measurement of sFLC. There is currently no reliable technique to detect non-linearity phenomena unless a serial dilution strategy is applied to every analysis. We recommend that laboratories routinely reporting sFLC results for clinical services need appropriate strategies for addressing these issues. Clinicians should be aware of these limitations in interpretation of sFLC assay for individual patients. Future guidelines should adopt action thresholds which are grounded firmly in test performance parameters.
© 2012 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23286947      PMCID: PMC3573291          DOI: 10.1111/cei.12011

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  28 in total

Review 1.  Immunochemical quantification of free immunoglobulin light chains from an analytical perspective.

Authors:  Takanari Nakano; Shuichi Miyazaki; Hidenori Takahashi; Akira Matsumori; Taro Maruyama; Tsugikazu Komoda; Atsuo Nagata
Journal:  Clin Chem Lab Med       Date:  2006       Impact factor: 3.694

2.  Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases.

Authors:  Jillian R Tate; Peter Mollee; Goce Dimeski; Andrew C Carter; Devinder Gill
Journal:  Clin Chim Acta       Date:  2006-07-14       Impact factor: 3.786

3.  Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.

Authors:  Marie-Christine Kyrtsonis; Theodoros P Vassilakopoulos; Nicoletta Kafasi; Sotirios Sachanas; Tatiana Tzenou; Argiroula Papadogiannis; Zacharoula Galanis; Christina Kalpadakis; Maria Dimou; Elias Kyriakou; Maria K Angelopoulou; Maria N Dimopoulou; Marina P Siakantaris; Evangelia M Dimitriadou; Styliani I Kokoris; Panayiotis Panayiotidis; Gerassimos A Pangalis
Journal:  Br J Haematol       Date:  2007-05       Impact factor: 6.998

4.  Serum free light chains; the need to establish local reference intervals.

Authors:  Rebecca J Pattenden; Stephen Y Rogers; Philip R Wenham
Journal:  Ann Clin Biochem       Date:  2007-11       Impact factor: 2.057

5.  Risk of antigen excess in serum free light chain measurements.

Authors:  Sandrine Daval; Arlette Tridon; Nicole Mazeron; Jean-Michel Ristori; Bertrand Evrard
Journal:  Clin Chem       Date:  2007-11       Impact factor: 8.327

6.  Appraisal of immunoglobulin free light chain as a marker of response.

Authors:  Angela Dispenzieri; Lijun Zhang; Jerry A Katzmann; Melissa Snyder; Emily Blood; Roberta Degoey; Kimberly Henderson; Robert A Kyle; Martin M Oken; Arthur R Bradwell; Philip R Greipp
Journal:  Blood       Date:  2008-03-25       Impact factor: 22.113

7.  Long-term biological variation of serum protein electrophoresis M-spike, urine M-spike, and monoclonal serum free light chain quantification: implications for monitoring monoclonal gammopathies.

Authors:  Jerry A Katzmann; Melissa R Snyder; S Vincent Rajkumar; Robert A Kyle; Terry M Therneau; Joanne T Benson; Angela Dispenzieri
Journal:  Clin Chem       Date:  2011-10-06       Impact factor: 8.327

8.  Monitoring serum free light chains in patients with multiple myeloma who achieved negative immunofixation after allogeneic stem cell transplantation.

Authors:  Ulrike Mösbauer; Francis Ayuk; Heike Schieder; Michael Lioznov; Axel R Zander; Nicolaus Kröger
Journal:  Haematologica       Date:  2007-02       Impact factor: 9.941

9.  Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system.

Authors:  C L H Snozek; J A Katzmann; R A Kyle; A Dispenzieri; D R Larson; T M Therneau; L J Melton; S Kumar; P R Greipp; R J Clark; S V Rajkumar
Journal:  Leukemia       Date:  2008-07-03       Impact factor: 11.528

10.  Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.

Authors:  Angela Dispenzieri; Robert A Kyle; Jerry A Katzmann; Terry M Therneau; Dirk Larson; Joanne Benson; Raynell J Clark; L Joseph Melton; Morie A Gertz; Shaji K Kumar; Rafael Fonseca; Diane F Jelinek; S Vincent Rajkumar
Journal:  Blood       Date:  2007-10-17       Impact factor: 22.113

View more
  2 in total

Review 1.  Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting.

Authors:  Paul G Richardson; Jesus F San Miguel; Philippe Moreau; Roman Hajek; Meletios A Dimopoulos; Jacob P Laubach; Antonio Palumbo; Katarina Luptakova; Dorothy Romanus; Tomas Skacel; Shaji K Kumar; Kenneth C Anderson
Journal:  Blood Cancer J       Date:  2018-11-09       Impact factor: 11.037

2.  Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials.

Authors:  Lucia Lopez-Anglada; Cecilia Cueto-Felgueroso; Laura Rosiñol; Albert Oriol; Ana Isabel Teruel; Ana Lopez de la Guia; Enrique Bengoechea; Luis Palomera; Felipe de Arriba; Jose Mariano Hernandez; Miquel Granell; Francisco Javier Peñalver; Ramon Garcia-Sanz; Juan Besalduch; Yolanda Gonzalez; Rafael Benigno Martinez; Miguel Teodoro Hernandez; Norma C Gutierrez; Paloma Puerta; Antonio Valeri; Bruno Paiva; Joan Blade; Maria-Victoria Mateos; Jesus San Miguel; Juan Jose Lahuerta; Joaquin Martinez-Lopez
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.